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A B S T R A C T
Background
Keratoconus is a condition of the eye that affects approximately 1 in 2000 people. The disease leads to a gradual increase in corneal
curvature and decrease in visual acuity with consequent impact on quality of life. Collagen cross-linking (CXL) with ultraviolet A
(UVA) light and riboflavin (vitamin B2) is a relatively new treatment that has been reported to slow or halt the progression of the
disease in its early stages.
Objectives
The objective of this review was to assess whether there is evidence that CXL is an effective and safe treatment for halting the progression
of keratoconus compared to no treatment.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2014, Issue 7), Ovid MEDLINE, Ovid MEDLINE In-
Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to August 2014), EMBASE
(January 1980 to August 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to August 2014),
Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to August 2014), OpenGrey (System for Information
on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), Clin-
icalTrials.gov (www.clinicaltrials.gov) and the World Health Organisation International Clinical Trials Registry Platform (ICTRP)
(www.who.int/ictrp/search/en). We used no date or language restrictions in the electronic searches for trials. We last searched the
electronic databases on 28 August 2014.
Selection criteria
We included randomised controlled trials (RCTs) where CXL with UVA light and riboflavin was used to treat people with keratoconus
and was compared to no treatment.
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Data collection and analysis
Two review authors independently screened the search results, assessed trial quality, and extracted data using standard methodological
procedures expected by Cochrane. Our primary outcomes were two indicators of progression at 12 months: increase in maximum
keratometry of 1.5 dioptres (D) or more and deterioration in uncorrected visual acuity of more than 0.2 logMAR.
Main results
We included three RCTs conducted in Australia, the United Kingdom, and the United States that enrolled a total of 225 eyes and
analysed 219 eyes. The total number of people enrolled was not clear in two of the studies. Only adults were enrolled into these studies.
Out of the eyes analysed, 119 had CXL (all using the epithelium-off technique) and 100 served as controls. One of these studies only
reported comparative data on review outcomes. All three studies were at high risk for performance bias (lack of masking), detection
bias (only one trial attempted to mask outcome assessment), and attrition bias (incomplete follow-up). It was not possible to pool data
due to differences in measuring and reporting outcomes. We identified a further three unpublished trials that potentially had enrolled
a total of 195 participants.
There was limited evidence on the risk of progression. Analysis of the first few participants followed up to one year in one study
suggested that eyes given CXL were less likely to have an increase in maximum keratometry of 1.5 D or more at 12 months compared
to eyes given no treatment, but the confidence intervals (CI) were wide and compatible with no effect or more progression in the CXL
group (risk ratio (RR) 0.12, 95% CI 0.01 to 2.00, 19 eyes). The same study reported the number of eyes with an increase of 2 D or
more at 36 months in the whole cohort with a RR of 0.03 favouring CXL (95% CI 0.00 to 0.43, 94 eyes). Another study reported
“progression” at 18 months using a different definition; people receiving CXL were less likely to progress, but again the effect was
uncertain (RR 0.14, 95% CI 0.01 to 2.61, 44 eyes). We judged this to be very low-quality evidence due to the risk of bias of included
studies, imprecision, indirectness and publication bias but noted that the size of the potential effect was large.
On average, treated eyes had a less steep cornea (approximately 2 D less steep) (mean difference (MD) -1.92, 95% CI -2.54 to -1.30,
94 eyes, 1 RCT, very low-quality evidence) and better uncorrected visual acuity (approximately 2 lines or 10 letters better) (MD -0.20,
95% CI -0.31 to -0.09, 94 eyes, 1 RCT, very low-quality evidence) at 12 months. None of the studies reported loss of 0.2 logMAR
acuity. The data on corneal thickness were inconsistent. There were no data available on quality of life or costs. Adverse effects were
not uncommon but mostly transient and of low clinical significance. In one trial, 3 out of 12 participants treated with CXL had
an adverse effect including corneal oedema, anterior chamber inflammation, and recurrent corneal erosions. In one trial at 3 years 3
out of 50 participants experienced adverse events including mild diffuse corneal oedema and paracentral infiltrate, peripheral corneal
vascularisation, and subepithelial infiltrates and anterior chamber inflammation. No adverse effects were reported in the control groups.
Authors’ conclusions
The evidence for the use of CXL in the management of keratoconus is limited due the lack of properly conducted RCTs.
P L A I N L A N G U A G E S U M M A R Y
Corneal collagen cross-linking for thinning of the transparent front part of the eye (’keratoconus’)
Review question
Is corneal collagen cross-linking (CXL) a good treatment for slowing down the progression of keratoconus?
Background
Keratoconus is a condition where the transparent front of the eye (cornea) gets thinner and begins to bulge. This leads to vision
problems, usually short-sightedness (distant objects appear blurred). The condition is more common in children and young adults
and can deteriorate over time. Initially glasses and contact lenses can help. If the disease progresses, the only option may be a corneal
transplant.
CXL is a new treatment for keratoconus. The eye doctor removes the outer layer of the cornea, puts in vitamin B2 eye drops, and then
treats the eye with ultraviolet A light radiation. This can be done in outpatients and takes about an hour.
Study characteristics
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The searches are current to August 2014. We found three randomised controlled trials, which were done in the United States, the
United Kingdom, and Australia. A total of 219 eyes were randomly allocated to treatment with CXL or no treatment. In all three
studies the surgery was done in the same way. None of the studies included children.
Key results
Eyes treated with CXL were less likely to have problems with progression of bulging compared to eyes that were not treated. However,
the studies were small and there were some concerns about the way they were done. It is therefore difficult to say exactly how much the
treatment helped. None of the studies reported the risk of eyesight getting worse but, on average, treated eyes had better vision (about
10 letters better) compared to untreated eyes. None of the studies reported on a change in quality of life for the participant. The main
adverse effects were inflammation and swelling; this occurred in approximately one in 10 participants.
Quality of the evidence
We judged the quality of the evidence to be very low because of problems in the way the studies were done and reported and the small
number of eyes included.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Corneal collagen cross-linking compared with no treatment for keratoconus
Patient or population: people with keratoconus
Settings: hospital
Intervention: corneal collagen cross-linking
Comparison: no or sham treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
No or sham treatment Corneal collagen cross-
linking
Progression (increase in
maximal keratometry of 1.
5 dioptres or more)
Follow-up: 12 months
400 per 1000 48 per 1000 (4 to 800) RR 0.12 (0.01 to 2.0) 19 eyes
(1)
⊕©©©
very low1−5
In the same study, in-
crease of 2 dioptres or
more at 36 months gave
a RRof 0.03 (95% CI 0.00
to 0.43, 94 eyes). A dif-
ferent study reported RR
of ‘ ‘ progression’’ at 18
months of 0.14 (95% CI
0.01 to 2.61, 44 eyes)
Steepness of the cornea
(maximal keratometry)
(measured using diop-
tres. A higher dioptre rep-
resents steeper cornea
and worse outcome)
Follow-up: 12 months
The mean maximal ker-
atometry increased in the
control group by 1.2 diop-
tres
The mean maximal ker-
atometry in the interven-
tion group was 1.92 diop-
tres less (better) (1.30 to
2.54 less)
94 eyes
(1)
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very low2,4,6
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Uncorrected visual acu-
ity (UCVA)
(measured using logMAR
scale. A score of 0 =
good vision, higher score
is worse vision)
Follow-up: 12 months
The mean UCVA in-
creased on average by 0.
06 logMAR units in the
control group
The mean UCVA in the
intervention groups was
0.20 logMAR units less
(i.e. better vision) (0.09
units less to 0.31 units
less)
94 eyes
(1)
⊕©©©
very low2,4,6
Another study reported
mean UCVA at 18 months
was 0.33 (Snellen dec-
imal equivalent) in 22
treated eyes and 0.21 in
22 untreated eyes. In the
treated eyes, the UCVA on
average changed by +0.
06 compared to -0.01 in
the control group
Corneal thickness at the
thinnest part of the
cornea
(measured in microns)
Follow-up: 12 months
The mean corneal thick-
ness decreased on aver-
age by 5.4 µm
The mean corneal thick-
ness in the interven-
tion group was 8.93 µm
thicker (0.60 µm thinner
to 18.46 µm thicker)
94 eyes
(1)
⊕©©©
very low2,3,4,7
We have reported the
study with the largest
numbers. Inconsistent re-
sults were seen in the
other 2 studies included
in this review. In 1 study
there was a change of -
31.4 µm in the treated
group at 3 months com-
pared to a change of -2.
3 µm in the sham treat-
ment group. In the other
study, corneal thickness
increased by 4 µm in 22
treated eyes compared to
6 µm in 22 untreated eyes
(mean difference -2 µm,
95% CI -33.10 to 29.01)
Absolute spherical
equivalent
(measured in dioptres)
Follow-up: 12 months
Themean absolute spher-
ical equivalent in the con-
trol groupwas -0.55 diop-
tres
Themean absolute spher-
ical equivalent in the in-
tervention group was 0.
65 dioptres higher (-0.37
to 1.67)
94 eyes
(1)
⊕©©©
very low2,3,4
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Quality of life
Follow-up: 12 months
Not reported.
Adverse effects
Follow-up: 12 months
In 1 trial 3/12 participants treated with corneal collagen cross-linking had an adverse effect including corneal oedema, anterior chamber inflammation, and a
recurrent corneal erosion. In 1 trial at 3 years, 3/50 participants experienced adverse events including mild diffuse corneal oedema and paracentral infiltrate,
peripheral corneal vascularisation, and subepithelial infiltrates and anterior chamber inflammation. No adverse effects were reported for untreated controls in any
of the studies
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence:
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded for indirectness (-1) as the studies reported different cutpoints and definitions of progression.
2 Downgraded for risk of bias (-1) as the studies were at high or unclear risk of performance, detection, attrition and selective outcome
reporting bias.
3 Downgraded for imprecision (-1) as the confidence intervals were wide and compatible with both benefit and harm.
4 Downgraded for publication bias (-1) as three unpublished studies (195 participants) identified.
5 Upgraded (+1) because the size of the effect was strong in both studies with approximate 90% relative risk reduction.
6 Downgraded for imprecision (-1) as results based on information from only 94 eyes.
7 Downgraded for inconsistency (-1) as different findings seen in the studies.
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B A C K G R O U N D
Description of the condition
Keratoconusmeans ’conical cornea’. It is a rare condition of the eye
that affects approximately 1 in 2000 people (Rabinowitz 1998).
The cornea is the main focusing surface of the eye. Keratoconus
reduces vision by altering the shape of the cornea so that it be-
comes stretched and thin, making the vision short-sighted, irreg-
ular, and distorted. The condition can affect one or both eyes and
can progress at varying rates.
Presentation
Initially, the patient may present with either a spherical cornea
or regular corneal astigmatism. Around the onset of puberty, or
earlier in some instances, the cornea begins to thin and protrude,
resulting in irregular astigmatism with what is usually a steep cur-
vature. Usually, over a period of the next 10 to 20 years, the pro-
cess continues until the progression gradually stops. The rate of
progression is variable. The severity of the disorder at the time
progression stops can range from very mild irregular astigmatism
to severe thinning and protrusion with scarring (Krachmer 1984).
Keratoconus is usually diagnosed during the second and third
decades of life. The ectasia progresses at a variable rate, although it
is more rapid at a younger age. Patients usually have myopic astig-
matism and are often suspected of having the condition by their
ophthalmologist or optometrist, or both, when a deterioration in
visual acuity that is no longer correctable by spectacles occurs.
Hydrops is an acute complication of keratoconus where there is
severe photophobia (sensitivity to light) and reduction in visual
acuity due to sudden stromal oedema. This is caused by breaks
in the Descemet’s membrane (deep layer in the cornea) due to
progressive ectasia.
Reported ocular associations of keratoconus include vernal kerato-
conjunctivitis, retinitis pigmentosa, and Leber’s congenital amau-
rosis. Systemic putative associations include many of the connec-
tive tissue disorders (for example Ehlers-Danlos and Marfan syn-
dromes), mitral valve prolapse, atopic dermatitis, and Down’s syn-
drome (Rabinowitz 1998). The outcomes of the Collaborative
Longitudinal Evaluation of Keratoconus (CLEK) Study showed
that keratoconus is not associated with increased risk of connective
tissue disease (Wagner 2007).
Identified predisposing factors include atopic history, especially
ocular allergies; rigid contact lens wear; and vigorous eye rubbing.
In 13.5% of cases there is a family history of the disease (Zadnik
1996). The inheritance in these cases is thought to exhibit variable
penetrance (Zadnik 1998). There is no sexual or racial predilec-
tion, although the incidence has been found to be higher or more
severe in certain ethnic groups (Georgiou 2004).
There is a general observation that elderly patients with kerato-
conus are not seen as often in clinics, and some have postulated
that the co-existing connective tissue disease may be contributory
to a decreased life expectancy. However, a study showing that peo-
ple with keratoconus do not have an increased mortality rate has
disputed this (Moodaley 1992).
Diagnosis
Keratoconus is unique among eye diseases in that it is typically
diagnosed during peak education, income-earning, and childbear-
ing years (Wagner 2007). Keratoconus is diagnosed based on clin-
ical examination and corneal topographic/tomographic analysis.
There are several clinical signs for which the presence or absence
of each is determined by the severity of the condition. An acute
angulation, made by the ectatic cornea, can be seen in the lower
lid on downgaze (Munson’s sign). Fleischer’s ring is a ring of ep-
ithelial iron deposition around the base of the cone. Vertical striae
(Vogt’s), which are fine stress lines in the Descemet’s membrane,
are detectable posteriorly. With time there is progressive thinning
of the corneal stroma, and the ectasia may be clinically detectable.
An ’oil droplet’ sign is often visible by direct ophthalmoscopy on
viewing the red reflex in a dilated eye. Scissoring and distortion
of the reflex can be seen on retinoscopy (Zadnik 1996). After re-
peated attacks of hydrops, stromal scarring may be visible.
Computer-assisted videophotokeratoscopy or Scheimpflug imag-
ing are sensitive means for detecting subtle changes in topography
on the anterior and posterior corneal surface and allow detailed
qualitative and quantitative analysis of corneal shape. Corneal to-
pography measures the steepening in terms of a dioptric power
map of the cornea. Various topographic indices have been pro-
posed for preclinical diagnosis of keratoconus (forme fruste) or the
diagnosis of keratoconus and grading of the severity of the disease.
Classification of keratoconus can be based on morphology, disease
evolution, ocular signs, and index-based systems of keratoconus.
Smolek, et al. have developed the Keratoconus Severity Index us-
ing a neural network approach to data collected from corneal to-
pography (Smolek 1997). Anothermethod used to classify the dis-
ease is the Amsler-Krumeich classification of keratoconus, which
depends on mean keratometry readings on the anterior curvature
sagittal map, thickness at the thinnest location, and the refractive
error of the patient. This classification is useful in choosing the
best approach for treating keratoconus. The keratoconus percent-
age index, which combines many of the earlier indices, has been
shown to have a high sensitivity in the videokeratoscopic identi-
fication of keratoconus (Li 2009). Keratoconus has three charac-
teristics seen by videokeratoscopy that are not present in normals:
an increased area of corneal power surrounded by concentric ar-
eas of decreasing power, inferior-superior power asymmetry, and
skewing of the steepest radial axes above and below the horizontal
meridian (Rabinowitz 1998). Keratoconus Severity Score is an-
other simple tool that was developed using common clinical mark-
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ers in addition to two corneal topographic indices: average corneal
power and higher-order first corneal surface wavefront root mean
square error, resulting in severity score (0 to 5) (McMahon 2006).
Belin/Ambrósio Enhanced Ectasia Display is an integrated appli-
cation in Pentacam system (Oculus Optikgeräte GmbH, Wetzlar,
Germany) that combines data from maximal keratometry, tomo-
graphic thickness distribution, and enhanced elevation to facili-
tate the detection of keratoconus (Ambrósio 2003; Belin 2007).
Additional metrics, such as epithelial thickness mapping with very
high frequency ultrasoundor high-resolutionoptical coherence to-
mography, can detect early keratoconus (Li 2012; Reinstein 2009;
Reinstein 2010). Newer techniques include analysing biomechan-
ical properties of the cornea using the Ocular Response Analyzer
(Reichert, Depew, NY), which so far is limited in its ability to
screen for keratoconus (Fontes 2010).
To date, the best and safest method of screening/diagnosing ker-
atoconus is to use as many data as possible in combination with
established clinical parameters.
The differential diagnosis of keratoconus includes keratoglobus,
pellucid marginal degeneration, and posterior keratoconus.
Aetiology and pathogenesis
Keratoconus has been reported in various clinical settings. It is
most commonly an isolated sporadic disorder, or it may be associ-
ated with other rare genetic disorders, Down’s syndrome, Leber’s
congenital amaurosis, connective tissue disorders, atopy, hard con-
tact lens wear, eye rubbing, and a positive family history of the
disorder. Several theories have been postulated regarding the aeti-
ology of keratoconus.
The biomechanical characteristics of the normal cornea result from
the collagen scaffold and collagen compound and their bonding
with the collagen fibrils. The three-dimensional configuration of
the collagen lamella fundamentally codetermines the cornea’s re-
sistance. Biochemical and immunohistochemical studies of the
matrix’s proteoglycans show differences between normal and ker-
atoconic corneas (Meek 2005; Raiskup-Wolf 2008).
Despite intensive biochemical investigation into the pathogenesis
of keratoconus, the underlying biochemical process and its aeti-
ologic basis remain poorly understood. Corneal thinning appears
to result from loss of structural components in the cornea; the
reason this occurs is not clear. Theoretically, the cornea can thin
because it has fewer collagen lamellae than normal, fewer collagen
fibrils per lamellae, closer packing of collagen fibrils, or various
combinations of these factors. These conditions may result from
defective formation of extracellular constituents of corneal tissue,
a destruction of previously formed components, an increased dis-
tensibility of corneal tissue with sliding collagen fibres or collagen
lamellae, or a combination of these mechanisms (Akhtar 2008;
Hayes 2008). However, some biochemical studies have demon-
strated that collagen composition in corneas with keratoconus was
unaltered. Biochemical assays and immunohistological studies of
corneas with keratoconus suggest that the loss of corneal stroma af-
ter digestion by proteolytic enzymes could be caused by increased
levels of proteases and other catabolic enzymes (Rabinowitz 1998).
Knowing the natural course of keratoconus is important in order
to understand the rate and severity of visual change. However, it
is difficult to fully appreciate the natural course of the disorder,
as usually the corneal changes have begun before the patient is
first seen and, after that, treatment may modify the natural course
(Krachmer 1984). CLEK study findings revealed that age appears
to be a factor in severity-related outcomes in keratoconus (Wagner
2007).
Disease progression
There is a general trend for the disease to progress, leading to a
gradual increase in corneal curvature and decrease in visual acuity
with consequent impact on quality of life (dependency, driving,
mental health, near activities, and role difficulties) (Wagner 2007).
There are no definitive criteria for progression, but parameters to
consider are change in refraction (both sphere and cylinder), un-
corrected and best-corrected visual acuity, and corneal topograph-
ical changes. The increase of the maximum keratometry reading
by 1 dioptre or more (≥ 1 D) remains the most frequently re-
ported index of disease progression (Caporossi 2010; Hersh 2011;
Raiskup-Wolf 2008; Wittig-Silva 2008).
Treatment
It is possible in the early stages to use spectacles to improve vision,
but as the disease progresses, rigid gas permeable contact lenses
often offer the best vision. Various contact lens designs and fittings
have been developed to adapt to the challenging needs of this dis-
ease, which typically progresses. The presence of corneal scarring,
significant thinning, and intolerance to contact lens wear are indi-
cations for corneal transplantation (keratoplasty). In high-income
countries, keratoconus is often the most common indication for
keratoplasty in young adults.
Several new therapeutic options have emerged, including refrac-
tive, optical, and tectonic interventions, which slow the progres-
sion of disease and/or delay more invasive treatment.
There are several methods for corneal transplantation. Penetrating
keratoplasty (replacement of the full thickness of the cornea) and,
more recently, deep anterior lamellar keratoplasty (replacement
of the front layers of the cornea only) are the most commonly
performed surgical interventions (Shimmura 2006).
Intrastromal rings (Intacs, Ferrara, Kerarings) are small devices
that can be implanted into the cornea in an attempt to flatten the
corneal profile to achieve a better uncorrected visual acuity and to
enhance contact lens tolerance (Rabinowitz 2007). However, this
procedure has its own limitations. Firstly, it does not affect the
underlying biochemical properties of the cornea. Secondly, there
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is a limit to how much corneal flattening can be achieved. Most
complications of intrastromal ring implantation can be reversed by
removing the segment, but serious complications can occur, such
as intraoperative corneal perforation, infectious keratitis (corneal
infection), damage to the central visual axis, or corneal melt (Boxer
Wachler 2003; Miranda 2003). Conductive keratoplasty has been
used in an attempt to reduce the severity of astigmatism (Naoumidi
2005). ’Bioptics’ is a sequential method of treating large and com-
plex refractive errors by several methods often involving intraoc-
ular lens implants. It has been used in keratoconus with treat-
ment algorithms that involve various combinations of intracorneal
rings, phacoemulsification, in-bag implants, iris clipped phakic
lenses, and posterior chamber phakic lenses (Leccisotti 2006). It is
likely that bioengineered corneas will be available in the future for
transplantation and may offer superior optical results to currently
available treatments (Carlsson 2003).
Collagen cross-linking (CXL) with ultraviolet A (UVA) light and
riboflavin (vitamin B2) is a relatively new treatment that has been
reported to slow the progression of the disease in its early stages
(Spoerl 1998; Wollensak 2003; Wollensak 2006). The improve-
ment in vision when combined with intracorneal ring segments
has been found to be greater than when using the segments alone
(Chan 2007).
Description of the intervention
CXL with UVA and topical riboflavin is carried out in sterile
conditions. There are twomain establishedmethods of performing
the procedure: corneal epithelium off or corneal epithelium on,
but different methods are currently being developed.
Corneal epithelium off
In this method (Wollensak 2003; Baiocchi 2009; Hayes 2008),
the epithelium of the central 7 mm of cornea is removed after
installing topical anaesthesia (for example proxymetacaine 0.5%).
The surface is then treated by the application of riboflavin 0.1%
solution (10 mg riboflavin-5-phosphate in 10 ml dextran 20%
solution which is iso-osmolar 0.1% riboflavin solution) for 30
minutes beginning 5 minutes before the start of irradiation. UVA
radiation of 370 nm wavelength and an irradiance of 3 mW/cm
2 at distance of 1 cm from the cornea is applied for a period of
30 minutes, delivering a dose of 5.4 J/cm2 (Wollensak 2006).
Antibiotic drops are instilled as prophylaxis and a bandage contact
lens is inserted, which is then removed at the follow-up visit once
epithelial healing is complete.
Variations of this protocol include the use of pilocarpine 1% pre-
operatively, a treatment area of 9 mm (Vinciguerra 2009), and
the selective use of steroids in the postoperative regimen to pre-
vent corneal haze (Vinciguerra 2012). Additionally, in eyes with
a corneal thickness less than 400 microns after epithelial removal,
there is a risk of corneal endothelial, lenticular, or intraocular UVA
damage (Kymionis 2012). To counter this, prior to application of
UVA a hypo-osmolar (hypotonic) solution of riboflavin is used
to swell the corneal stroma and hence increase the corneal thick-
ness through a denuded epithelium. This technique was tried on
corneal thickness (after epithelial removal) between 320 to 400
microns (Hafezi 2009)
Corneal epithelium on
In this method, the corneal epithelium is kept on (Chan 2007;
Pinelli 2007). In 2003, Boxer Wachler, et al. proposed a slight
modification of the treatment using pre-operative anaesthetic eye-
drops containing benzalkonium chloride to loosen the tight junc-
tions of the corneal epithelial cells (Boxer Wachler 2003). The use
of benzalkonium chloride may allow transepithelial cross-linking
treatment without removal of the epithelium. This technique was
designed to reduce postoperative pain and improve patient com-
fort. This modification is known as C3-R (Baiocchi 2009; Vicente
2010). In this technique, 30 minutes before the UVA treatment,
1 drop of pilocarpine 2% is installed and riboflavin solution is
started (1 drop every 2 minutes with minimum 16 drops over 30
minutes). Topical anaesthetic drop is started 20minutes before the
treatment (1 drop every 4 minutes, repeated 4 times). Treatment
with UVA irradiation lasts for a total of 30 minutes, adding 1 drop
riboflavin every 5 minutes.
In both techniques, a bandage contact lens is inserted at the end of
the procedure and removed after five days. A number of modified
riboflavin formulations have been introduced to facilitate diffusion
through the corneal epithelium (Caporossi 2013; Koppen 2011).
Different techniques
A hybrid technique currently used in some centres is to perform
epithelial disruption in the 9 mm zone using a special disrupter to
create pockmarks in the corneal epithelium (Rechichi 2013). The
primary goal is to maintain as much live epithelium as possible
but also promote riboflavin penetration. The secondary goal is to
reduce eye inflammation and to get the contact lens out of the
patient within 48 hours. Riboflavin eye drops are instilled after
disruption and every 2 to 5 minutes for at least 30 minutes before
UVA radiation treatment.
Recent studies aiming to reduce the procedure time to 9 minutes
have used higher power (up to 30 mW/cm2 compared to 3 mW/
cm2 in the standard procedure). The goal is to achieve a rapid
treatment protocol by using higher intensity UVA and shorter ir-
radiation time. This technique (known as flash-linking or rapid
cross-linking) aims to keep an equivalent energy dose to the stan-
dard irradiation of 3 mW/cm2 whilst reducing the treatment time
from 30 minutes to 9 minutes (Schumacher 2011).
Another technique currently being investigated is iontophoresis
transcorneal delivery technique, which is a method of facilitating
the penetration of riboflavin through the cornea through the use
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of a low-intensity electrical current. Compared to the classic tech-
nique, iontophoresis shortens the time needed for riboflavin pen-
etration and the duration of exposure to UVA radiation and does
not require epithelium removal (Arboleda 2014; Mastropasqua
2014).
How the intervention might work
CXL employs the photosensitiser riboflavin (vitamin B2), which
when exposed to longer wavelength ultraviolet light (370 nm
UVA), will induce chemical reactions (free radical production) in
the corneal stroma and ultimately result in the formation of cova-
lent bonds between the collagen molecules, fibres, and microfib-
rils. This increase in collagen bonding is thought to prevent further
thinning and ectasia and as such slow or halt the progression of
keratoconus. Some pre-clinical investigations, including biochem-
ical and biophysical measurements, have demonstrated enhanced
corneal rigidity and greater biomechanical stability of the cornea
following this treatment (Raiskup-Wolf 2008; Wollensak 2003).
Wollensak, et al. have further demonstrated a significant increase
in collagen fibre diameter as the underlying histopathologic corre-
late after CXL. Increased resistance to pepsin digestion after cross-
linking has been found, which might be important for kerato-
conus, as a significantly elevated activity of collagenases has previ-
ously been noted (Wollensak 2004).
Why it is important to do this review
Asmentioned above, CXL is the only treatment that claims to slow
down the progression of keratoconus. CXL is carried out largely
unregulated with very few standardised criteria available for iden-
tification of the ideal patient to benefit from the treatment. Kera-
toconus is very asymmetrical and at times a very slowly progressive
disease; in particular, it is well known that the rate of progression
slows with age (Hovakimyan 2012; Krachmer 1984). Short-term
data from trials are available, but robust evidence on the long-
term efficacy and safety of CXL is not and is needed. Keratomet-
ric indices are at present the main indicators of treatment effect.
Changes in corneal biomechanics, which this treatment purports
to induce, have not been studied in vivo (Ashwin 2009). This re-
view examined evidence from the current literature (and will ex-
amine future trial results as and when they become available) to
provide clinicians with answers about what they can expect of this
relatively new treatment. This review also provided an evidence-
based reference point for people with keratoconus who seek val-
idated information regarding the efficiency of the specific treat-
ment.
O B J E C T I V E S
The objective of this review was to assess whether there is evidence
that CXL is an effective and safe treatment for halting the progres-
sion of keratoconus compared to no treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
We included all studies in which participants had been diagnosed
with keratoconus. We have excluded no participants according to
age. We had planned to exclude studies where participants had
previous treatment, but in the event we did not identify any such
studies.
Types of interventions
We included trials that compared collagen cross-linking (CXL)
(with riboflavin and ultraviolet A (UVA)) to no treatment. We
excluded trials that compared different ways of doing CXL and
did not have a control (no treatment) group. We excluded trials
examining the use of this treatment for conditions other than
keratoconus.
Types of outcome measures
Primary outcomes
Two indicators were used to measure disease progression at 12
months after treatment:
• Increase in maximal keratometry (Kmax) of more than 1.5
D
• Worsening in uncorrected visual acuity of more than 0.2
logMAR
Secondary outcomes
Other indicators of disease progression:
• Mean maximal keratometry in dioptres at 12 months after
treatment
• Mean uncorrected visual acuity at 12 months after
treatment
• Mean average corneal power in dioptres at 12 months after
treatment
• Mean corneal thickness at the thinnest part of the cornea
12 months after treatment
10Corneal collagen cross-linking for treating keratoconus (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Mean absolute spherical equivalent at 12 months after
treatment
• Contact lens intolerance developed within 12 months of
treatment
Safetymeasures: We looked at all adverse outcomes related toCXL
reported in the included studies including the following:
• Infectious keratitis
• Corneal haze and scarring
• Glare and halo
• Reduction in uncorrected or best-corrected visual acuity
• Corneal epithelial defect
• Anisometropia
• Diplopia
• Induced astigmatism
• Reduction in contrast sensitivity
• Fluctuating vision (during the day or from day to day)
• Increased or decreased light sensitivity
• Endothelial cell damage as indicated by fall in endothelial
cell density
Quality-of-life outcomes
One aim of this review was to summarise any validated quality-
of-life measures used.
Economic data
One aim of this review was to summarise any data on cost or
economics reported in the included studies.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (which contains the Cochrane Eyes and Vision Group Reg-
ister) (CENTRAL; 2014, Issue 7), Ovid MEDLINE, Ovid
MEDLINE In-Process and Other Non-Indexed Citations, Ovid
MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to Au-
gust 2014), EMBASE (January 1980 to August 2014), Latin
American and Caribbean Health Sciences Literature Database
(LILACS) (1982 to August 2014), Cumulative Index to Nurs-
ing and Allied Health Literature (CINAHL) (1982 to August
2014), OpenGrey (System for Information on Grey Litera-
ture in Europe) (www.opengrey.eu/), the metaRegister of Con-
trolled Trials (mRCT) (www.controlled-trials.com), ClinicalTri-
als.gov (www.clinicaltrials.gov) and the World Health Organisa-
tion International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We used no date or language re-
strictions in the electronic searches for trials. We last searched the
electronic databases on 28 August 2014.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), LILACS (Appendix 4), CINAHL (Appendix 5), OpenGrey
(Appendix 6),mRCT (Appendix 7), ClinicalTrials.gov (Appendix
8) and the ICTRP (Appendix 9).
Searching other resources
We searched other resources by handsearching book chapters, con-
tacting clinical experts, and searching the reference lists of all in-
cluded studies. We emailed all contact authors from the included
studies asking for further information on their methodology and
results.
Data collection and analysis
Selection of studies
Two review authors (ES, RK) independently assessed all retrieved
citations regarding eligibility for inclusion. The same two review
authors obtained full-text copies of definitely or potentially rele-
vant studies and assessed them carefully.We had non-English trial
reports translated to determine whether theymet the inclusion cri-
teria. We also recorded the reasons for excluding studies. In cases
where there were disagreements between the two review authors,
a third review author was involved.
Data extraction and management
Two review authors (ES, JE) independently extracted data. We
recorded on a form information about the methods used in the
trial along with the following:
1. Details of participants (age, gender, setting, number in each
group, grade of keratoconus, and comparability at baseline).
2. Details of intervention(s).
3. Outcomes (including adverse effects). For dichotomous
data, the number of participants assigned to each intervention
was collected and the number of participants who experienced
the event. For continuous data, the mean and standard
deviations were collected or calculated, or the median and
interquartile range if the data were skewed, for each study.
4. Percentage of participants for whom no outcome data could
be obtained.
Disagreements were resolved by discussion.
Assessment of risk of bias in included studies
Two review authors (ES, RK) independently assessed for risk of
bias based on the following parameters and using Cochrane’s tool
for assessing risk of bias as specified in Chapter 8 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
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1. Method of randomisation: We considered the method used
to generate the random sequence within the trials at low risk of
bias if it involved a computer random number generator,
random number tables, shuffled cards, or envelopes.
2. Allocation concealment: Low risk would be central
allocation or numbered, sealed, opaque envelopes.
3. Masking of participants, personnel, and outcome
assessment.
4. Participant attrition: Were rates of follow-up similar in
comparison groups? Was the analysis based on an intention-to-
treat?
5. Selective reporting in terms of outcomes, time points,
subgroups, or analyses.
We assessed and graded each parameter as follows: low risk of bias,
high risk of bias, and unclear risk of bias.
We emailed all first authors of included trials twice for clarification
wherewe judged risk of bias to be unclear, but receivedno response.
Measures of treatment effect
The primary outcome variables (increase in maximum keratom-
etry of 1.5 D or more and loss of 0.2 logMAR visual acuity or
more) were dichotomous, and we used the risk ratio (RR) as the
measure of treatment effect. Secondary outcomes were continu-
ous; for these, we used the mean difference as a measure of treat-
ment effect. We planned to report medians in the event that data
were skewed, but where data were reported, means were available.
Unit of analysis issues
We included both within-person and parallel group studies. We
did not do any meta-analysis. For within-person studies, we calcu-
lated confidence intervals for themeasures of effect without taking
into account the pairing (due to lack of appropriately reported
data). This is a conservative assumption. We requested raw data
from the authors via email but the authors did not supply.
In future editions of this review thatmay includemeta-analyses, we
will analysewithin-person andparallel group studies separately and
then combine estimates using the generic inverse variancemethod.
If data are not adequately analysed in the published reports, we
will ask for raw data from the authors. If paired studies have been
used, we will assess whether or not eyes were symmetric at baseline
to see whether or not a paired approach seemed plausible. We will
also examine whether or not effect estimates from paired studies
seem consistent with those from unpaired studies.
Dealing with missing data
We contacted authors regarding missing data. We did an available
case analysis and judged the extent to which attrition bias might
be a problem in the ’Risk of bias’ table. We did not look at the
potential impact ofmissingdata in a sensitivity analysis (as planned
in our protocol (Hamada 2013)) due to the sparcity of data and
lack of meta-analysis.
Assessment of heterogeneity
We planned to assess heterogeneity by looking at the clinical and
methodological diversity of the studies and by examining the forest
plots and I2 statistic as described in Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011) .
However, this was not required as we did not do anymeta-analysis.
Assessment of reporting biases
To assess publication bias, we performed a search of clinical trials
registers to identify studies that have been completed but may not
have been published. We addressed selective outcome reporting as
part of the ’Risk of bias’ assessment (Assessment of risk of bias in
included studies).
Data synthesis
We did not conduct any meta-analysis because we found only
three eligible studies, and these studies did not report the required
outcomes in the correct format to enable the data to be pooled.
In future updates of this review, we will meta-analyse studies pro-
vided it is sensible to do so, for example, we find no evidence
of substantial heterogeneity (I2 less than 50%), or the effect esti-
mates are in the same direction. We will use a fixed-effect model
if there are three or fewer studies and a random-effects model if
more studies are available.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available in future updates of this review,
we will perform a subgroup analysis to assess whether severity of
keratoconus has an effect on response to treatment. We will use
keratometry-based classification of disease severity (mild less than
45 D, moderate 45 D to 52 D, severe greater than 52 D) (Zadnik
1996).
Sensitivity analysis
In future updates, providing sufficient data are available, we will
do two sensitivity analyses: first, excluding studies at high risk of
bias in one or more domains and second, excluding studies where
missing data were imputed.
Summary of findings table
We prepared a summary of findings table presenting relative and
absolute risks. One author (JE) graded the overall quality of the
evidence for each outcome using the GRADE classification (
www.gradeworkinggroup.org/) and the other authors checked this
grading. We included the following outcomes in the summary of
findings table.
• Progression
• Steepness of the cornea
• Uncorrected visual acuity
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• Corneal thickness
• Absolute spherical equivalent
• Quality of life
• Adverse effects
These outcomes were not selected a priori as the summary of
findings tables was not planned at the protocol stage.
R E S U L T S
Description of studies
Results of the search
The electronic searches yielded a total of 670 references (Figure
1). After removing duplicates, we reviewed 482 references and dis-
carded 431 as not relevant to the scope of the review. We obtained
51 full-text reports to assess for potential inclusion in the review
and included eight reports of three studies (see Characteristics
of included studies) and excluded 40 reports of 38 studies (see
Characteristics of excluded studies). We sought two additional re-
ports of studies originally found on clinicaltrials.gov to help as-
certain if these studies should be excluded. We also identified one
ongoing trial (see Characteristics of ongoing studies) and aim to
include this study in the review when completed, if appropriate.
There were also four reports of three potentially relevant studies
for which results were not currently available. If we are able to
access the results for these studies, we could include them in fur-
ther updates of this review (see Characteristics of studies awaiting
classification).
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Figure 1. Results from searching for studies for inclusion in the review
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Included studies
Study populations
We included three RCTs that enrolled a total of 225 eyes and anal-
ysed 219 eyes.Out of these eyes, 119 hadCXLwith the epithelium
off technique and 100 served as controls. The three trials were
conducted in Australia (Wittig-Silva 2008), the United Kingdom
(O’Brart 2011), and the United States (Hersh 2011). The number
of eyes in each study was 100, 48, and 71, respectively. It was not
clear how many participants were involved in Wittig-Silva 2008
or Hersh 2011; 24 people were included in O’Brart 2011.
All three trials randomly allocated eyes to treatment. O’Brart
2011 was a within-person study, but for the other two trials it
was not clear how eyes within person were allocated. In Hersh
2011, apart fromkeratoconics, participantswith iatrogenic corneal
ectasia were studied, but the reports from the two groups were
reported separately, and also of note is the fact that the control
group was only half the size of the intervention group, and all
controls were treated at three months.
All three trials included participants where there was topographic
or refractive evidence of progression of keratoconus, but while
O’Brart 2011 and Wittig-Silva 2008 excluded eyes where corneal
pachymetry was less than 400µm, Hersh 2011 used as exclusion
criterion corneal pachymetry of less than 300µm.
Interventions and comparators
All three trials used the same technique forCXLwithminimal vari-
ations. Epithelium was removed under topical anaesthesia, topi-
cal isotonic riboflavin solution of 0.1% was applied, and then the
corneawas treatedwithUVA radiation (370 nm at 3mW/cm2 ) for
30 minutes. In the trials by Wittig-Silva 2008 and O’Brart 2011,
there was no sham treatment for controls, while in Hersh 2011,
the following sham treatment was used for controls: riboflavin was
applied without epithelial debridement, followed by sham treat-
ment in which the UVA light was not turned on.
Outcomes and follow-up
Wittig-Silva 2008 reported 12-months results for a subset of the
whole cohort and subsequently published 12-months and 36-
months results for a larger group of participants. Hersh 2011 re-
ported findings at 12 months, and O’Brart 2011 at 18 months
follow-up.
Funding sources
Hersh 2011 was supported in part by Peschke Meditrade GmbH,
Zurich, Switzerland, and an unrestricted grant to the Department
of Ophthalmology, University of Medicine and Dentistry of New
Jersey-New JerseyMedical School fromResearch to Prevent Blind-
ness, Inc., New York, New York, USA.
O’Brart 2011 was funded by Guy’s and St. Thomas’ NHS Foun-
dation Trust, own account, NHS R&D Support Funding.
Wittig-Silva 2008 was funded by the Royal Victorian Eye and
Ear Hospital Research Fund, Eye Research Australia Foundation,
Scholarship for Postgraduate Studies (Faculty of Medicine and
University of Melbourne), and Contact Lens Society of Australia
Excluded studies
We excluded 38 studies. See Characteristics of excluded studies.
Risk of bias in included studies
See Figure 2; Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Overall the trials were judged to be at low risk of selection bias.
O’Brart 2011 and Wittig-Silva 2008 described computer-gener-
ated allocation schedules, and O’Brart 2011 used shuffled en-
velopes.
All three trials described methods to conceal the allocation. Hersh
2011 and O’Brart 2011 used sealed envelopes; Wittig-Silva 2008
described how the schedule was kept secure and managed by staff
not involved in the trial.
Blinding
All three trials were judged to be at high risk of performance bias.
In two trials (O’Brart 2011; Wittig-Silva 2008), no attempt was
made to mask participants or caregivers to the treatment (and
indeed this would have been difficult due to the invasive nature
of the treatment). Hersh 2011 had a sham treatment arm but
reported that participants were aware of their randomly assigned
group, so the significance of the sham treatment was unclear.
O’Brart 2011 was judged to be at low risk for detection bias as the
visual acuity measurements were done by a masked observer who
was not otherwise involved in the trial. For Hersh 2011, it was
unclear the extent to which the outcome assessments were masked,
as they did have a sham treatment group. We judged Wittig-Silva
2008 to be at high risk of detection bias, as they described the
trial as “unmasked”, and the treatment groups were quite different
(treated/not treated).
Incomplete outcome data
O’Brart 2011 was judged to be at low risk of attrition bias because
it was a within-person study and therefore follow-up was equal
between the two treatment groups.
OverallWittig-Silva 2008 was judged to be at high risk of attrition
bias due to differential follow-up: At one year 46 (92%) treated
and 41 (82%) control eyes were followed up. Using last observa-
tion carried forward, data for 46 treated and 48 control eyes were
reported. Over 3 years, 21 eyes in the control group left the trial, of
which 12 were treated with CXL, 5 had corneal transplants, and 4
withdrew for personal reasons. In the treatment group, five people
(eyes) withdrew for personal reasons. This unequal loss to follow-
up meant that the control group was followed up, on average, for
less time than the treatment group.
For Hersh 2011 it was unclear.
Selective reporting
We did not have access to study protocols and in general felt we
could not accurately judge the extent of selective reporting.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
See Analysis 1.1
Increase in maximal keratometry of more than 1.5 D at 12
months after treatment
Wittig-Silva 2008 reported an interim analysis after 19 eyes (out
of a total of 100 eyes) had been followed up to 1 year. Zero out
of 9 eyes treated with CXL experienced an increase in maximal
keratometry of 1.5 D or more at 12 months compared to 4 out of
10 eyes in the control group (risk ratio (RR) 0.12, 95% confidence
interval (CI) 0.01 to 2.00).
Wittig-Silva 2008 did not report 12-months data for this outcome
for the whole cohort, but at 36 months no treated eyes had in-
creased by 2 D or more (out of 46 treated eyes), compared to 19
out of 48 eyes in the control group (RR 0.03, 95% CI 0.00 to
0.43). It must be noted that in Wittig-Silva 2008, 26 eyes were
not followed up for the full 36 months, and last observation car-
ried forward was used. The loss to follow-up was different be-
tween the two groups: 21 eyes in the control group left the trial,
of which 12 were treated with CXL, 5 had corneal transplants,
and 4 withdrew for personal reasons. In the treatment group, five
people (eyes) withdrew for personal reasons. This unequal loss to
follow-up meant that the control group was followed up, on aver-
age, for less time than the treatment group. The effect of this bias
will probably be in favour of the control group (as keratoconus is
a progressive disease, and the control group did not have so much
time to progress). This means that the measure of effect is likely
to be an underestimate of the size of the effect.
O’Brart 2011 did not report this outcome but did report “pro-
gression” at 18 months. Progression was defined as “an increase
in both simulated keratometry (Orbscan II) and cone apex power
by >0.75 D and consistent worsening of other measurements”.
According to this definition, 0 out of 22 treated eyes compared to
3 out of 22 untreated eyes progressed over the time period (RR
0.14, 95% CI 0.01 to 2.61).
Hersh 2011 did not report this outcome.
Deterioration in uncorrected visual acuity of more than 0.2
logMAR at 12 months after treatment
None of the studies reported this outcome.
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Secondary outcomes
See Analysis 1.2.
Mean maximal keratometry in dioptres at 12 months after
treatment
Wittig-Silva 2008 reported that maximal keratometry in treated
eyes decreased on average by 0.72 D (standard deviation (SD)
1.0) over 12 months in contrast to control eyes, where maximal
keratometry increased on average by 1.2 D (SD 1.94), (mean
difference (MD) -1.92 D, 95% CI -2.54 D to -1.30 D).
O’Brart 2011 did not report this outcome.
Hersh 2011 reported “no significant differences” between treated
and control eyes at three months but did not report the data.
Mean uncorrected visual acuity at 12 months after
treatment
Wittig-Silva 2008 reported that uncorrected visual acuity (UCVA)
logMAR score in treated eyes decreased on average by 0.14 (SD
0.3) over 12 months in contrast to control eyes, where UCVA
logMAR increased on average by 0.06 (SD 0.21) (MD -0.20, 95%
CI -0.31 to -0.09).
O’Brart 2011 reported that mean UCVA at 18 months was 0.33
(Snellen decimal equivalent) in 22 treated eyes and 0.21 in 22
untreated eyes. In the treated eyes, the UCVA on average changed
by +0.06 compared to -0.01 in the control group. This gives a
MD of 0.07 Snellen decimal equivalent (95% CI -0.04 to 0.18,
estimated from P value of 0.2)
Hersh 2011 reported “no significant differences” between treated
and control eyes at three months but did not report the data.
Mean average corneal power in dioptres at 12 months after
treatment
Wittig-Silva 2008 reported preliminary data on a subset of the
trial followed up to one year. Average corneal power in treated
eyes decreased on average by 1.2 D (estimate from graph, SD not
reported, 9 eyes) over 12 months in contrast to control eyes, where
corneal power increased on average by 1.10 D (SD not reported,
11 eyes). If we assume a SD of 1 D in both groups (based on other
data in the paper), then this gives a MD of -2.30, 95% CI -3.18
to -1.42. This outcome was not reported for the whole cohort at
one year.
O’Brart 2011 reported that average corneal power decreased in
the treated eyes over 18 months, but there was a discrepancy in
the paper such that it was not clear whether the decrease was 0.62
D or 0.66 D. There was an increase of 0.14 D in the control
group. As a P value was provided for the comparison between -
0.66 D and 0.14 D (less than 0.001), we have estimated the CIs
for the difference between -0.66 D and 0.14 D. This gives a mean
difference of -0.8 D (95% CI -0.36 to -1.24).
Hersh 2011 reported “no significant differences” between treated
and control eyes at three months but did not report the data.
Mean corneal thickness at the thinnest part of the cornea 12
months after treatment
Wittig-Silva 2008 reported that corneal thickness at the thinnest
part of the cornea in treated eyes increased on average by 3.53 µm
(SD 23.7, 46 eyes) over 12 months in contrast to control eyes,
where corneal thickness decreased on average by 5.4 µm (SD 23.4,
48 eyes) (MD 8.93, 95% CI -0.60 to 18.46).
In Hersh 2011 there was a change in pachymetry (thinnest part of
the cornea) of -31.4 µm (SD not reported) in the treated group at
three months compared to a change of -2.3 µm (no SD reported)
in the control group.
In O’Brart 2011 ultrasonic central corneal pachymetry increased
by 4 µm in 22 treated eyes compared to 6 µm in 22 untreated eyes.
(MD -2 µm, 95% CI -33.01 to 29.01 (CI estimated from p-value
of 0.9)).
Mean absolute spherical equivalent at 12 months
Wittig-Silva 2008 reported change in absolute spherical equivalent
in treated eyes of 0.1D (SD2.6, 46 eyes) over 12months compared
to control eyes, where absolute spherical equivalent changed by -
0.55 D (SD 2.42, 48 eyes). This gives a MD of 0.65 D, 95% CI
-0.37 to 1.67.
Contact lens intolerance developed within 12 months of
treatment
Only one study mentioned contact lens intolerance (O’Brart
2011). Three out of 22 participants were contact lens intolerant
pre-operatively. Two of these three participants ended up having
intrastromal corneal ring segment insertion.
Adverse outcomes
Only O’Brart 2011 and Wittig-Silva 2008 described adverse ef-
fects in their papers. In O’Brart 2011, overall three participants
were noted to have an adverse effect, including corneal oedema,
anterior chamber inflammation, and a recurrent corneal erosion.
In Wittig-Silva 2008, 36-month results document 3 participants
with adverse events: 1 case with mild diffuse corneal oedema and
a paracentral infiltrate, 1 case with peripheral corneal vascularisa-
tion, and 1 case with subepithelial infiltrates and anterior chamber
inflammation. No adverse effects were reported for any controls
in any of the studies.
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Quality-of-life outcomes
Hersh 2011 reported this for the cohort of treated participants
but did not provide a comparison between treated and untreated
participants. The other studies did not report quality of life.
Economic data
The included studies did not report economic data.
D I S C U S S I O N
Summary of main results
We found three eligible trials that compared CXL versus no treat-
ment, but one of these trials reported very little useable data. It
was not possible to pool data due to differences in measuring and
reporting outcomes. All three trials were at high risk of bias. We
identified a further three unpublished trials.
There was indirect information on the risk of progression (which
we defined as increase of 1.5Dormore inmaximumkeratometry).
The available data suggest that there may be in the order of an
80% to 90% relative risk reduction in progression over 12months,
but we are very uncertain as to the size of the effect (Summary of
findings for the main comparison).
Other data reported suggested that on average treated eyes had a
less steep cornea (approximately 2 D less steep) and better uncor-
rected visual acuity (approximately 2 lines or 10 letters better), but
again we judged the quality of the evidence to be very low, as it
was largely derived from one trial at high risk of bias and there was
the possibility of publication bias. The data on corneal thickness
were inconsistent.
There were no data available on quality of life.
Adverse effects were not uncommon. In 1 trial, 3 out of 12 partic-
ipants treated with CXL had an adverse effect, including corneal
oedema, anterior chamber inflammation, and a recurrent corneal
erosion. In 1 trial at 3 years, 3 out of 50 participants had ex-
perienced adverse events, including mild diffuse corneal oedema
and a paracentral infiltrate, peripheral corneal vascularisation, and
subepithelial infiltrates and anterior chamber inflammation.
Overall completeness and applicability of
evidence
Overall the evidence is incomplete, with only three trials reported
with small sample sizes and at high risk of bias. Important out-
comes, such as risk of visual acuity loss and quality-of-life mea-
sures, have not been reported. Only one trial followed up partic-
ipants for longer than one year. As keratoconus is a slowly pro-
gressing disease, longer follow-up may be important.
With respect to applicability, the participants included in these
studies were reasonably representative of patients likely to be in-
terested in this treatment. We did not find any studies in children,
which is an important omission in the evidence. The surgical tech-
niques used are similar to those used in clinical practice.
Quality of the evidence
The overall quality of the evidence was judged to be very low
(Summary of findings for themain comparison). Themain reasons
for downgrading the evidence included risk of bias in the included
studies, imprecision, indirectness and publication bias.
Potential biases in the review process
We used standard methods expected by Cochrane. Search screen-
ing and data extractionwere done independently by two review au-
thors. We have clarified and amended the protocol for this review
a little--in particular clarifying the comparison group and refining
the outcomes. We do not believe that this will have introduced
any bias into the review but note that the outcomes selected for
presentation in the summary of findings table were not planned
a priori but were selected while the review was in progress. We
have documented all changes in Differences between protocol and
review.
Agreements and disagreements with other
studies or reviews
Although there are notmany RCTs available, we did find a few sys-
tematic reviews andmeta-analyses in the literature. The major one
is performed by NICE (NICE 2013; Craig 2014), which includes
RCTs and prospective studies. This review concluded that there is
evidence for the effectiveness of CXL in halting the progression of
keratoconus. Performingmeta-analysis by comparing qualitatively
different maximal keratometry (Kmax) (NICE 2013; Gore 2013)
is clinically questionable, as different topography instruments have
been used in different studies. Although most studies have used
increase in Kmax of more than or equal to 1 D to report progres-
sion, we have chosen 1.5 D, as repeatability variations and limi-
tations in measurement accuracy of most topographers is a well-
known factor (Szalai 2012). In fact, in their meta-analysis, Gore
2013, by using 1 D difference in Kmax to measure progression
and regression, found that 10% of controls were found to have
regression, something that does not normally happen in kerato-
conic corneas, confirming that 1.5D ismore appropriate clinically.
Another meta-analysis, by Chunyu 2014, concluded that further
research from randomised trials is necessary to confirm whether
CXL is an effective treatment. The difficulty in performing meta-
analysis of RCTs is once more highlighted as we can see that the
way studies are reported can be misleading for review authors. For
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example, the study by Henriquez 2011 identified by NICE as an
RCT does not fit the strict criteria to be included in our review,
as controls were recruited separately and their methodology did
not include random allocation of treatment. Additionally, Chunyu
2014 did not identify the fact that Hersh 2011 was published in
multiple publications which may have introduced bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite the numerous prospective and retrospective studies avail-
able in the literature and the fact that CXL seems to be accepted
worldwide as a breakthrough treatment in the management of
keratoconus, evidence is limited due to the lack of properly con-
ducted RCTs. If strict criteria are used and only data from RCTs
accepted, then there is a lack of evidence that CXL is indeed an
effective treatment in halting the progression of keratoconus.
Implications for research
Higher-quality studies are needed before an appropriate meta-
analysis can be conducted to confirm the importance of this treat-
ment. However, things look promising, as there seem to be mul-
tiple ongoing registered studies looking into the effectiveness of
CXL, as well as studies looking intomodifications of the treatment
protocols.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hersh 2011
Methods Parallel group RCT
Results reported by eye, but more eyes enrolled than people and unclear whether there
was also within-person randomisation
Study recruited participants with ectasia due to keratoconus and iatrogenic (after surgery
for myopia). Only the keratoconus participants were included in this review
Participants Country: USA
Number of people randomised: not reported, (77 eyes)
Average age: Not reported
% women: Not reported
Inclusion criteria:
• 14 years of age or older
• axial topography pattern consistent with keratoconus
• an inferior-superior ratio greater than 1.5 on topography mapping
• corrected distance visual acuity worse than 20/20
• diagnosis of progressive keratoconus, which was defined as 1 or more of the
following changes over a period of 24 months: an increase of 1.00 D or more in the
steepest keratometry measurement, an increase of 1.00 D or more in manifest cylinder,
an increase of 0.50 D or more in MRSE.
Exclusion criteria:
• history of corneal surgery
• corneal pachymetry less than 300 mm
• history of chemical injury or delayed epithelial healing, pregnancy or lactation
during the course of the study
Interventions • CXL, following epithelial removal, with riboflavin 0.1% and UVA (370 nm at 3
mW/cm2) (n = 49 eyes)
• Sham treatment (n = 28 eyes)
“The sham control group received riboflavin 0.1% ophthalmic solution alone. In this group,
the epitheliumwas not removed. Riboflavin was administered topically every 2 minutes for 30
minutes. Next, the cornea was exposed to a sham treatment in which the UVA light was not
turned on, during which time riboflavin was administered topically every 2 minutes for an
additional 30 minutes. The sham control patients were followed for 3 months postoperatively,
at which point the study eye crossed over to the treatment group and received full CXL
treatment.” Hersh 2011 page 150
Outcomes From clinical trials registry entry:
Primary outcome:
• Change in keratometry at 3 and 12 months
No secondary outcomes listed.
The following outcomes were reported in various publications:
• Change in maximum keratometry values (Hersh 2011)
• Change in average keratometry values (Hersh 2011)
• Change in BSCVA (Hersh 2011)
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Hersh 2011 (Continued)
• Refractive sphere, astigmatism, MRSE (Hersh 2011, reported not statistically
significant only, no data)
• Adverse effects (Hersh 2011)
• Patient questionnaire on visual functioning including driving, reading, double
vision, glare, halos, dryness, pain, foreign body sensation (Brooks 2012, intervention
group only)
• Corneal thickness (Greenstein 2011)
• Higher-order aberrations (Greenstein 2011, intervention group only)
• Biomechanical changes (Greenstein 2011a)
Follow-up: 1, 3, 6, and 12 months
Note: As the sham control group was treated at 3 months, comparisons are valid up to
3 months only
Notes Date study conducted: December 2007 to April 2011 (from trials register), but main
publication accepted for publication in 2010
Funding: “Supported in part by Peschke Meditrade GmbH, Zurich, Switzerland, and an
unrestricted grant to the Department of Ophthalmology, UMDNJ-New JerseyMedical School
from Research to Prevent Blindness, Inc., New York, New York, USA”
Conflict of interest: “No author has a financial or proprietary interest in any material or
method mentioned.”
“Dr. Hersh is a paid medical consultant to Avedro, Inc.”
Trial registration: NCT00647699
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was computer generated ...”
Hersh 2011 page 150
Allocation concealment (selection bias) Low risk “... on the procedure day, a sealed envelope
was opened revealing whether the eye would
be in the sham or treatment group” Hersh
2011 page 150
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Patients were aware of their randomly as-
signed group.”Hersh 2011 page 150
but the control group was given a sham
procedure, it is not clear why if participants
were told which group they were in
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Control groupwas given a shamprocedure,
but participants were aware of their status
(see above)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Follow-up not reported.
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Hersh 2011 (Continued)
Selective reporting (reporting bias) Unclear risk We did not have access to the study proto-
col and could not accurately judge the ex-
tent of selective reporting
O’Brart 2011
Methods Within-person RCT
Eyes randomly allocated to treatment, treated and untreated groups compared using
unpaired t tests
Participants Country: UK
Number of people randomised: 24 (48 eyes)
Average age: 30 years (range 21 to 42)
% women: 21
Inclusion criteria:
• early to moderate keratoconus (grade I to III according to the Amsler-Krumeich
classification) with documented evidence or reported progression with reduced
uncorrected visual acuity or BSCVA by more than 1 line and/or worsening of refractive
or corneal astigmatism, keratometry, or cone apex power by 0.75 D over the previous
18 months.
Exclusion criteria:
• advanced keratoconus where corneal irregularity/scarring prevented acquisition of
accurate refractive and topographic data
• central corneal thickness < 400 mm
• age < 18 years
• pregnancy
• other active ocular pathology
• previous anterior segment surgery
• diabetes
• inability to remove rigid contact lenses for 3 weeks prior to examinations
Interventions • CXL, following epithelial removal, with riboflavin 0.1% and UVA (370 nm at 3
mW/cm2) (n = 24 eyes)
• Observation (n = 24 eyes)
Outcomes • Best corrected visual acuity
• Uncorrected visual acuity
• Spherical equivalent refractive error
• Refractive astigmatism
• Orbscan-simulated keratometry
• Adverse events
Follow-up: 1 week; 3, 6, 12, 18 months (outcomes reported at 18 months)
Notes Date study conducted: June 2006 to December 2007 (anticipated recruitment dates as
reported on trials register entry)
Funding: Guy’s and St. Thomas’ NHS Foundation Trust, own account, NHS R&D
Support Funding
Conflict of interest: reported “none”
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O’Brart 2011 (Continued)
Trial registration: ISRCTN08013636
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eyes were randomised to receive treatment
using a shuffled closed envelope system by a
member of staff not involved in the study.
There were 36 envelopes (18 for right and 18
left). Sixteen right eyes and eight left eyes were
randomly selected for treatment.” Page 1520
Allocation concealment (selection bias) Low risk “Eyes were randomised to receive treatment
using a shuffled closed envelope system by a
member of staff not involved in the study.
There were 36 envelopes (18 for right and 18
left). Sixteen right eyes and eight left eyes were
randomly selected for treatment.” Page 1520
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
masked due to the nature of the interven-
tion. Subjective measurements (visual-acu-
ity assessment and refraction) in partici-
pants were undertaken by a masked ob-
server (PP) not involvedwith either the ran-
domisation process or the surgical proce-
dure
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Subjective measurements (visual-acuity as-
sessment and refraction) were undertaken by
a masked observer (PP), not involved with ei-
ther the randomisation process or the surgical
procedure.” Page 1520
Incomplete outcome data (attrition bias)
All outcomes
Low risk Within-person study, so follow-up equal
between treatment groups
Selective reporting (reporting bias) Unclear risk We did not have access to the study proto-
col and could not accurately judge the ex-
tent of selective reporting
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Wittig-Silva 2008
Methods Parallel group RCT
If both eyes of a participant were eligible, each eye was randomised independently
Participants Country: Australia
Number of people randomised: Not stated. 100 eyes
Average age: 26 years
% women: 43
Inclusion criteria:
• age 16 to 50 years
• unequivocal clinical and videokeratographic diagnosis of keratoconus
• clinically significant progression of the ectasia over the preceding 6 to 12 months.
Progression was considered to be confirmed if at least 1 or more of the following
criteria were met: an increase of at least 1.00 D in the steepest simulated Kmax derived
from computerized videokeratography or in the steepest meridian measured by manual
keratometry; an increase in astigmatism as determined by manifest subjective refraction
of at least 1.00 D; an increase of 0.50 D in MRSE; or a 0.1 mm or more decrease in
back optic zone radius of the best-fitting contact lens.
Exclusion criteria:
• minimum corneal thickness 400 µm
• axial corneal scarring
• previous refractive surgery or other corneal surgery
• history of chemical burns, severe infections, or other corneal or ocular surface
disease
• pregnant or breastfeeding at the time of the treatment
Interventions • CXL, following epithelial removal, with riboflavin 0.1% and UVA (370 nm at 3
mW/cm2) (n = 47 eyes)
• Observation (n = 49 eyes)
Eyes randomised to control were offered compassionate CXL (no earlier than 6 months
after randomisation) during the course of study if continuing and significant progression
was noted
Outcomes As reported on clinical trials register entry:
Primary outcome:
• Maximum simulated keratometry value measured using computerised
videokeratography (Orbscan II; Bausch and Lomb Surgical, Utah). Participants
recruited after November 2007 were also imaged with Scheimpflug imaging (Pentacam
HR, Oculus, Germany).
Secondary outcomes:
• Uncorrected visual acuity expressed as logMAR
• BSCVA expressed as logMAR
• Subjective refraction (sphere and cylinder) performed by trained orthoptists
• Minimum simulated keratometry value measured using computerised
videokeratography (Orbscan II; Bausch and Lomb Surgical, Utah). Participants
recruited after November 2007 were also imaged with Scheimpflug imaging (Pentacam
HR, Oculus, Germany).
• Corneal thickness at the thinnest point using ultrasound pachymetry (Pachymeter
SP-3000; Tomey, Nagoya, Japan), computerised videokeratography (Orbscan II;
Bausch and Lomb Surgical, Utah) and Scheimpflug imaging (Pentacam HR, Oculus,
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Wittig-Silva 2008 (Continued)
Germany)
• Endothelial cell density using the SP-2000 Specular Microscope (Topcon Corp,
Tokyo, Japan)
• Intraocular pressure using the Tono-Pen XL (Medtronic, Jacksonville, Florida)
and Goldmann applanation tonometer (Haag-Streit, Koeniz, Switzerland)
Follow-up: 5 years (on clinical trial register).
Outcomes reported to date: BSCVA and maximum and average keratometry values at
3, 6, 12, 24, and 36 months. At 12 months, results from 46 treated and 48 control eyes
reported using LOCF
Notes Date study conducted: June 2006 to June 2009 (as reported on trials register entry)
Funding: Royal Victorian Eye and Ear Hospital Research Fund, Eye Research Australia
Foundation, Scholarship for Postgraduate Studies (Faculty of Medicine and University
of Melbourne), and Contact Lens Society of Australia
Conflict of interest: reported “The authors have no financial interest in the materials
presented herein.”
Trial registration: ACTRN12613000143729
Paper was published in 2011. https://www.anzctr.org.au/Trial/Registration/TrialReview.
aspx?id=363630
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Enrolled eyes were randomized separately to
either the treatment or control groups using a
computer generated randomization plan with
blocks of 10. If both eyes of 1 patient qualified
for participation in the study, each eye was
randomized independently” Page 813, Wit-
tig-Silva 2014
Allocation concealment (selection bias) Low risk “The randomisation plan was maintained in
a secure location by a staff member in another
hospital department not involved with the re-
cruitment or conduct of the study” Page 813,
Wittig-Silva 2014
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was described as open label
(masking not used) on clinical trials registry
entry
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was described as open label
(masking not used) on clinical trials registry
entry. “All images were acquired and ana-
lyzed in an unmasked manner”. Page 813,
Wittig-Silva 2014
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Wittig-Silva 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Differential follow-up: At one year 46
(92%) treated and 41 (82%) control eyes
followed up to 12 months. Using LOCF,
data for 46 treated and 48 control eyes
were reported. Over 3 years, 21 eyes in the
control group left the trial, of which 12
were treatedwithCXL, 5 had corneal trans-
plants, and 4 withdrew for personal rea-
sons. In the treatment group, five people
(eyes) withdrew for personal reasons. This
unequal loss to follow-up meant that the
control group was followed up, on average,
for less time than the treatment group
Selective reporting (reporting bias) High risk Different cut-points used at different time
periods: 1.5D or more reported at one year
and 2D or more reported at 36 months
BSCVA: best spectacle-corrected visual acuity
CXL: Collagen cross-linkage
D: dioptre
Kmax: maximal keratometry
LOCF: last observation carried forward
logMAR: logarithm of the minimum angle of resolution
MRSE: manifest refraction spherical equivalent
RCT: randomised controlled trial
UVA: ultraviolet A
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alessio 2013 Not an RCT
Caporossi 2010 Not an RCT
Caporossi 2013 Not an RCT
Coskunseven 2009 Not an RCT
Doors 2009 Not an RCT
Gkika 2012 Not an RCT
Goldich 2010 Not an RCT
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(Continued)
Greenstein 2013 Not an RCT
Grewal 2009 Not an RCT
Hallahan 2014 Not an RCT
Henriquez 2011 Not an RCT
Holopainen 2011 Not an RCT
ISRCTN04451470 RCT comparing epithelium on or off
ISRCTN29378493 RCT comparing use of contact lenses before surgery or not
Jordan 2014 Not an RCT
Kilic 2012 Not an RCT
Koller 2009 Not an RCT
Kránitz 2014 Not an RCT
Mastropasqua 2013 RCT comparing two different cross-linking methods
Mazzotta 2007 Not an RCT
NCT01143389 RCT comparing two different riboflavin regimens
NCT01152541 RCT comparing two different riboflavin regimens
NCT01181219 RCT comparing epithelium on or off
NCT01325298 RCT comparing two different UVA dosing regimens
NCT01344187 RCT comparing riboflavin versus placebo
NCT01459679 RCT comparing three different treatment regimens
NCT01464268 RCT comparing two different riboflavin regimens
NCT01643226 RCT comparing riboflavin versus placebo
NCT01708538 RCT comparing epithelium on or off
NCT01868620 RCT comparing iontophoretic CXL with standard CXL
NCT01972854 RCT comparing riboflavin versus placebo
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(Continued)
NCT02009709 RCT comparing two different irradiance levels
Poli 2013 Not an RCT
Razmjoo 2014 RCT comparing total and partial removal of the epithelium
Rechichi 2013 Not an RCT
Salman 2013 Not an RCT
Viswanathan 2013 Not an RCT
Wisse 2014 Not an RCT
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
NCT00626717
Methods RCT
Participants 30
Interventions CXL with riboflavin and UVA light versus sham treatment
Outcomes Keratoconus progression and endothelial cell loss
Notes Primary completion date: December 2012
Principal investigator confirmed publication under review March 2015
NCT00841386
Methods RCT
Participants Target:150
Interventions CXL with riboflavin and UVA irradiation versus sham treatment
Outcomes • Best corrected visual acuity
• Spherical equivalent power of the cornea (best spectacle refraction)
• Kmax: the maximum corneal curvature
• Average corneal power of the cornea in the central 4 mm
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NCT00841386 (Continued)
Notes Primary completion date: December 2011
Email sent to principal investigator October 2014 and March 2015 with no response
Serapicos 2009
Methods RCT
Participants Target: 15
Interventions CXL with riboflavin and UVA light versus control
Outcomes Stop progression of keratoconus in cornea imaging exams
Notes Primary completion date: August 2009
Abstract reporting first two cases published 2009
Email sent to principal investigator October 2014 and February 2015 with no response
CXL: Collagen cross-linkage
RCT: randomised controlled trial
UVA: ultraviolet A
Characteristics of ongoing studies [author-defined order]
NCT01604135
Trial name or title Collagen crosslinking for keratoconus--a randomized controlled clinical trial (CXL-RCT)
Methods RCT
Participants Target: 200
Interventions CXL with riboflavin and UVX
Outcomes Kmax (non-progression)
Starting date May 2012
Contact information Madeleine Zetterberg, 00463431000, madeleine.zetterberg@anatcell.gu.se
Notes NCT01604135
BSCVA: best spectacle-corrected visual acuity
CXL: Collagen cross-linkage
Kmax: maximal keratometry
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RCT: randomised controlled trial
UVA: ultraviolet A
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D A T A A N D A N A L Y S E S
Comparison 1. Corneal collagen cross-linking versus sham or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary outcomes 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Progression (increase in
maximal keratometry) at 12
months after treatment
2 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Progression (Increase in
maximal keratometry) at 36
months after treatment
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Secondary outcomes 2 Mean Difference (Fixed, 95% CI) Totals not selected
2.1 Mean maximal
keratometry in dioptres at 12
months after treatment
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Mean uncorrected visual
acuity at 12 months after
treatment
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Change in mean corneal
thickness (µm) at the thinnest
part of the cornea 12 months
after treatment
2 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Mean average corneal
power in dioptres at 12 months
after treatment
2 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Mean absolute spherical
equivalent at 12 months after
treatment
1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Corneal collagen cross-linking versus sham or no treatment, Outcome 1
Primary outcomes.
Review: Corneal collagen cross-linking for treating keratoconus
Comparison: 1 Corneal collagen cross-linking versus sham or no treatment
Outcome: 1 Primary outcomes
Study or subgroup CXL Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Progression (increase in maximal keratometry) at 12 months after treatment
O’Brart 2011 (1) 0/22 3/22 0.14 [ 0.01, 2.61 ]
Wittig-Silva 2008 (2) 0/9 4/10 0.12 [ 0.01, 2.00 ]
2 Progression (Increase in maximal keratometry) at 36 months after treatment
Wittig-Silva 2008 (3) 0/46 19/48 0.03 [ 0.00, 0.43 ]
0.01 0.1 1 10 100
Favours CXL Favours control
(1) At 18 months: progression was ”an increase in both simulated keratometry (Orbscan II) and cone apex power by >0.75 D and consistent worsening of other
measurements”
(2) Increase of 1.5D or more
(3) Increase of 2D or more
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Analysis 1.2. Comparison 1 Corneal collagen cross-linking versus sham or no treatment, Outcome 2
Secondary outcomes.
Review: Corneal collagen cross-linking for treating keratoconus
Comparison: 1 Corneal collagen cross-linking versus sham or no treatment
Outcome: 2 Secondary outcomes
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean maximal keratometry in dioptres at 12 months after treatment
Wittig-Silva 2008 -1.92 (0.316461) -1.92 [ -2.54, -1.30 ]
2 Mean uncorrected visual acuity at 12 months after treatment
Wittig-Silva 2008 -0.2 (0.053622) -0.20 [ -0.31, -0.09 ]
3 Change in mean corneal thickness ( m) at the thinnest part of the cornea 12 months after treatment
O’Brart 2011 (1) -2 (15.8198) -2.00 [ -33.01, 29.01 ]
Wittig-Silva 2008 8.93 (4.859851) 8.93 [ -0.60, 18.46 ]
4 Mean average corneal power in dioptres at 12 months after treatment
O’Brart 2011 (2) -0.8 (0.22449) -0.80 [ -1.24, -0.36 ]
Wittig-Silva 2008 -2.3 (0.449467) -2.30 [ -3.18, -1.42 ]
5 Mean absolute spherical equivalent at 12 months after treatment
Wittig-Silva 2008 0.65 (0.518618) 0.65 [ -0.37, 1.67 ]
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(1) 18 months follow-up
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Keratoconus
#2 keratoconus
#3 ectasia
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Collagen
#6 collagen cross near/2 link*
#7 collagen crosslink*
#8 CCL
#9 CXL
#10 C3R
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#11 (#5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 (#4 AND #11)
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp keratoconus/
14. keratoconus.tw.
15. ectasia.tw.
16. or/13-15
17. exp collagen/
18. (collagen cross adj2 link$).tw.
19. collagen crosslink$.tw.
20. CCL.tw.
21. CXL.tw.
22. C3R.tw.
23. or/17-22
24. 16 and 23
25. 12 and 24
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
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19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp keratoconus/
34. keratoconus.tw.
35. ectasia.tw.
36. or/33-35
37. exp collagen/
38. (collagen cross adj2 link$).tw.
39. collagen crosslink$.tw.
40. CCL.tw.
41. CXL.tw.
42. C3R.tw.
43. or/37-42
44. 36 and 43
45. 32 and 44
Appendix 4. LILACS search strategy
keratoconus or ectasia and collagen cross link$ or collagen crosslink or CCL or CXL
Appendix 5. CINAHL (EBSCO) search strategy
S24 S12 and S23
S23 S15 and S22
S22 S16 or S17 or S18 or S19 or S20 or S21
S21 C3R
S20 CXL
S19 CCL
S18 collagen crosslink*
S17 collagen cross link*
S16 (MH “Collagen”)
S15 S13 or S14
S14 ectasia
S13 keratoconus
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TX allocat* random*
S10 (MM “Quantitative Studies”)
S9 (MM “Placebos”)
S8 TX placebo*
S7 TX random* allocat*
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S6 (MM “Random Assignment”)
S5 TX randomi* control* trial*
S4 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl*
n1mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S3 TX clinic* n1 trial*
S2 PT Clinical trial
S1 (MH “Clinical Trials+”)
The search filter for trials at the beginning of the CINAHL strategy was developed by the Scottish Intercollegiate Guidelines Network
(SIGN 2010).
Appendix 6. OpenGrey search strategy
keratoconus AND collagen cross
Appendix 7. metaRegister of Controlled Trials search strategy
(keratoconus or ectasia) and (collagen cross or CCL or CXL)
Appendix 8. ClinicalTrials.gov search strategy
(keratoconus OR ectasia) AND (collagen cross OR CCL OR CXL)
Appendix 9. ICTRP search strategy
keratoconus OR ectasia = Condition AND collagen cross OR CCL OR CXL = Intervention
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol for this review was not explicit about how modifications of the CXL technique were to be handled. We decided to include
only trials of treatment versus control in this review. There are a large number of ongoing studies that compare modifications of the
technique and they will be included in future separate Cochrane reviews.
In this review’s original protocol we defined mainly dichotomous secondary outcome measures using various cutpoints. However, these
cutpoints were not reported. Trials in this field generally report these outcomes as continuous measures. Given the sparcity of the data,
we felt that we would lose potentially relevant information, so we amended the secondary outcome measures to allow collection of
continuous data.
The protocol did not specify the methods to be used when compiling the summary of findings table. We have prepared a summary of
findiings table but note the outcomes for presenting were selected at the same time as the review was being prepared.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Collagen [∗chemistry]; Confidence Intervals; Cross-Linking Reagents [∗therapeutic use]; Disease Progression; Keratoconus [∗therapy];
Photosensitizing Agents [radiation effects; therapeutic use]; Randomized Controlled Trials as Topic; Riboflavin [radiation effects;
therapeutic use]; Ultraviolet Therapy
MeSH check words
Adult; Humans
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